Localized delivery of chemotherapy to the cervix for radiosensitization

Gynecologic Oncology

Volumn 127, Issue 1, 2012, Pages 121-125

  Hodge, Lucy S ^a   Downs Jr , Levi S ^a   Chura, Justin C ^a   Thomas, Sajeena G ^a   Callery, Patrick S ^b   Soisson, A Patrick ^b   Kramer, Paul ^b   Wolfe, Stephen S ^b   Tracy, Timothy S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Carcinoma; Cervix; Drug delivery; Gemcitabine; Radiosensitization; Uterus

Indexed keywords

2',2' DIFLUORODEOXYURIDINE; DIAZEPAM; DRUG METABOLITE; GEMCITABINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; DRUG EXPOSURE; DRUG TARGETING; DRUG TISSUE LEVEL; ENDOMETRIUM CARCINOMA; FEMALE; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; HYSTERECTOMY; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; PRIORITY JOURNAL; RADIOSENSITIZATION; ULTRAVIOLET SPECTROSCOPY; UTERINE CERVIX; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA;

ANTIMETABOLITES, ANTINEOPLASTIC; CERVIX UTERI; DEOXYCYTIDINE; DIAZEPAM; DRUG DELIVERY SYSTEMS; DRUG INTERACTIONS; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; RADIATION-SENSITIZING AGENTS;

EID: 84865691695     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.07.097     Document Type: Article

References (26)

1. W.A. Peters III, P.Y. Liu, R.J. Barrett II, R.J. Stock, B.J. Monk, and J.S. Berek Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix J Clin Oncol 18 2000 1606 1613
2. P.G. Rose, B.N. Bundy, E.B. Watkins, J.T. Thigpen, G. Deppe, and M.A. Maiman Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer N Engl J Med 340 1999 1144 1153
3. H.M. Keys, B.N. Bundy, F.B. Stehman, L.I. Muderspach, W.E. Chafe, and C.L. Suggs III Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma N Engl J Med 340 1999 1154 1161
4. M. Morris, P.J. Eifel, J. Lu, P.W. Grigsby, C. Levenback, and R.E. Stevens Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer N Engl J Med 340 1999 1137 1143
5. C.W. Whitney, W. Sause, B.N. Bundy, J.H. Malfetano, E.V. Hannigan, and W.C. Fowler Jr. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study J Clin Oncol 17 1999 1339 1348
6. E.M. Swisher, R.E. Swensen, B. Greer, H. Tamimi, B.A. Goff, and R. Garcia Weekly gemcitabine and cisplatin in combination with pelvic radiation in the primary therapy of cervical cancer: a phase I trial of the Puget Sound Oncology Consortium Gynecol Oncol 101 2006 429 435
7. P.G. Rose, K. Degeest, S. McMeekin, and N. Fusco A phase I study of gemcitabine followed by cisplatin concurrent with whole pelvic radiation therapy in locally advanced cervical cancer: a Gynecologic Oncology Group study Gynecol Oncol 107 2007 274 279
8. Duenas-Gonzalez A, Zarba JJ, Patel F, Alcedo JC, Beslija S, Casanova L, Pattaranutaporn P, Hameed S, Blair JM, Barraclough H, Orlando M. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol 29: 1678-85.
9. J. Umanzor, M. Aguiluz, C. Pineda, S. Andrade, M. Erazo, and C. Flores Concurrent cisplatin/gemcitabine chemotherapy along with radiotherapy in locally advanced cervical carcinoma: a phase II trial Gynecol Oncol 100 2006 70 75
10. A. Duenas-Gonzalez, L. Cetina-Perez, C. Lopez-Graniel, A. Gonzalez-Enciso, E. Gomez-Gonzalez, and L. Rivera-Rubi Pathologic response and toxicity assessment of chemoradiotherapy with cisplatin versus cisplatin plus gemcitabine in cervical cancer: a randomized Phase II study Int J Radiat Oncol Biol Phys 61 2005 817 823
11. P. Rose New treatment paradigm for locally advanced cervical cancer? Nat Rev Clin Oncol 8 2011 388 390
12. S.S. Wolfe Uterine uptake of diazepam and quantification by gas chromatography/mass spectrometry Pharmaceutical Science 2003 West Virginia University Morgantown 1 70
13. M.N. Kirstein, I. Hassan, D.E. Guire, D.R. Weller, J.W. Dagit, and J.E. Fisher High-performance liquid chromatographic method for the determination of gemcitabine and 2′,2′-difluorodeoxyuridine in plasma and tissue culture media J Chromatogr B Analyt Technol Biomed Life Sci 835 2006 136 142
14. M. Dobrinas, J. Cornuz, L. Pedrido, and C.B. Eap Influence of cytochrome P450 oxidoreductase genetic polymorphisms on CYP1A2 activity and inducibility by smoking Pharmacogenet Genomics 22 2012 143 151
15. L. Cattel, M. Airoldi, L. Delprino, R. Passera, P. Milla, and F. Pedani Pharmacokinetic evaluation of gemcitabine and 2′,2′- difluorodeoxycytidine-5′-triphosphate after prolonged infusion in patients affected by different solid tumors Ann Oncol 17 Suppl. 5 2006 v142 v147
16. R. Grunewald, H. Kantarjian, M.J. Keating, J. Abbruzzese, P. Tarassoff, and W. Plunkett Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (gemcitabine) administration in leukemia Cancer Res 50 1990 6823 6826
17. E. Mini, S. Nobili, B. Caciagli, I. Landini, and T. Mazzei Cellular pharmacology of gemcitabine Ann Oncol 17 Suppl. 5 2006 v7 v12
18. J. Sigmond, R.J. Honeywell, T.J. Postma, C.M. Dirven, S.M. de Lange, and K. van der Born Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer Ann Oncol 20 2009 182 187
19. M. Pennycooke, N. Chaudary, I. Shuralyova, Y. Zhang, and I.R. Coe Differential expression of human nucleoside transporters in normal and tumor tissue Biochem Biophys Res Commun 280 2001 951 959
20. J.R. Mackey, L.L. Jennings, M.L. Clarke, C.L. Santos, L. Dabbagh, and M. Vsianska Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers Clin Cancer Res 8 2002 110 116
21. J.R. Kroep, W.J. Loves, C.L. van der Wilt, E. Alvarez, I. Talianidis, and E. Boven Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity Mol Cancer Ther 1 2002 371 376
22. X. Farre, E. Guillen-Gomez, L. Sanchez, D. Hardisson, Y. Plaza, and J. Lloberas Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors Int J Cancer 112 2004 959 966
23. M. Molina-Arcas, S. Marce, N. Villamor, I. Huber-Ruano, F.J. Casado, and B. Bellosillo Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells Leukemia 19 2005 64 68
24. C. Hiller, U. Bock, S. Balser, E. Haltner-Ukomadu, and M. Dahm Establishment and validation of an ex vivo human cervical tissue model for local delivery studies Eur J Pharm Biopharm 68 2008 390 399
25. D.S. Shewach, and T.S. Lawrence Radiosensitization of human solid tumor cell lines with gemcitabine Semin Oncol 23 1996 65 71
26. B. Pauwels, A.E. Korst, H.A. Lambrechts, G.G. Pattyn, C.M. de Pooter, and F. Lardon The radiosensitising effect of difluorodeoxyuridine, a metabolite of gemcitabine, in vitro Cancer Chemother Pharmacol 58 2006 219 228